Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection and Omnipaque™ Injection

Inclusion Criteria: * Women of childbearing potential who are sexually active with a non-sterile male partner must be using a medically acceptable form of birth control for the duration of the trial and for 30 days after the last dose of study drug * BMI within the range of 18.5-35 kg/m2, inclusive, and body weight \> 45 kg * No significant disease or abnormal laboratory values * Normal vital signs, without any clinically significant abnormalities * Normal 12-lead electrocardiogram, without any clinically significant abnormalities of rate, rhythm or conduction * Nonsmokers defined as not having smoked in the past 3 months prior to dosing * Estimated glomerular filtration rate (eGFR) of \> 60 mL/min/1.73 m2 Exclusion Criteria: * Known hypersensitivity or allergy to iohexol, CAPTISOL®, Omnipaque™ or its excipients * Known hypersensitivity or allergy to iodine or radio-opaque dyes * Women who are pregnant or breast feeding * History or presence of asthma or other pulmonary disease, thyroid disease (hypo- or hyperthyroidism), hepatitis or other liver disease * Any disease or condition (medical or surgical) which, in the opinion of the investigator, might compromise a major system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk * Abnormal laboratory values which are considered clinically significant * Positive screen for Hepatitis B (HbsAg, Hepatitis B Surface Antigen), Hepatitis C (anti HCV, Hepatitis C Antibody), or HIV (anti-HIV 1/2) * Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dose * Use of medication other than topical products without significant systemic absorption, hormonal contraceptives and hormone replacement therapy * Unwilling to refrain from consumption of alcohol within 48 hours prior to each dose administration and during any in-patient period. * Positive urine drug screen, positive alcohol breath test or positive cotinine test at screening and upon check-in to the study facility * History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit * Illicit drug use,significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction * A history of difficulty with donating blood or with the insertion of large-calibre catheter * Donation of plasma (500 mL) within 7 days prior to drug administration. * Hemoglobin \< 128 g/L (males) and \< 115 g/L (females) and hematocrit \< 0.36 L/L (males) and \< 0.32 L/L (females) at screening * Any history of photosensitivity